Anagenics (ASX:AN1) said it is in ongoing discussions with the Australian Securities Exchange to lift the suspension on the trading of its securities, according to a Friday filing with the Australian bourse.
The health, beauty, and wellness firm's securities have been on a voluntary trading halt since Sept. 4, 2024.
In the same filing, the company confirmed US-based Roquefort Therapeutics' proposed sale of Lyramid to Pleiades Pharma. It has an intellectual property license agreement with Lyramid granting it rights to receive royalties from products utilizing its midkine portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.